Clay Siegall is the President, CEO and Board Chairman of Seattle Genetics founded in 1998. Siegall is a scientist who researches on cancer therapies. He developed Seattle Genetics on a scientific foundation of meticulous research and administration as well as a passion for serving cancer patients.
He has led Seattle Genetics to its leadership in the development of antibody-drug conjugates (ADC). Siegall also helped in the 2011 FDA approvals of the company’s primary drug ADC, ADCETRIS. In conjunction with Takeda Pharmaceuticals Ltd, ADCETRIS is an approved global brand in over 65 countries. Seattle Genetics has franchised its ADC technology, with strategic partners including Genentech, GlaxoSmithKline, Pfizer, and AbbVie. Together, they have generated more than $350 million in sales to date. Dr. Siegall has led Seattle Genetics’ crowdfunding activities, raising more than $1.2 billion.
In 2013 biotechnology firm Mirna Therapeutics, the developers of microRNA therapeutics, appointed Clay Siegall, Ph.D., Chairman, CEO and President Seattle Genetics, as a member of the Board of Directors. He was named by Mirna as an expert scientist to help in the development of microRNA- therapies. Dr. Clay Siegall is firmly commitment to science research and development of cancer treatments through continuous studies and production of innovative ideal cancer therapies.
Dr. Siegall previously worked with Pharmaceutical Research institution- Bristol-Myers Squibb from 1991-1997.He also served at the National Institutes of Health and the National Cancer Institute, from 1988 -1991. Clay serves as Boards of Director at the Washington Roundtable, Alder Biopharmaceuticals and Ultragenyx Pharmaceutical.
Dr. Siegall has received several awards, including the 2013 Maryland University Alumnus for Natural Sciences, Math and Computers. He also awarded the Ernst & Young Pacific Northwest Executive of the Year 2012. He has authored over seventy scientific journals and holds fifteen patents. Dr. Clay Siegall earned his Bachelor of Science degree in Zoology from Maryland University. He further earned his Ph.D. in Genetics from the University of George Washington.
Clay developed a passion for studying genetics when he watched father tragically die from Cancer. He was 24 years old. He sought to help patients through Seattle Genetics. Dr. Siegall has 30 years of experience in the study and development of cancer therapies. Clay recommends young people to continuously learn and network with experts across various professions.